Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer: A diagnostic challenge and management dilemma.

Papalampros A, Mpaili E, Moris D, Sarlanis H, Tsoli M, Felekouras E, Trafalis DT, Kontos M.

Medicine (Baltimore). 2019 Apr;98(16):e14989. doi: 10.1097/MD.0000000000014989.

2.

The Role of Isothiocyanates as Cancer Chemo-Preventive, Chemo-Therapeutic and Anti-Melanoma Agents.

Mitsiogianni M, Koutsidis G, Mavroudis N, Trafalis DT, Botaitis S, Franco R, Zoumpourlis V, Amery T, Galanis A, Pappa A, Panayiotidis MI.

Antioxidants (Basel). 2019 Apr 18;8(4). pii: E106. doi: 10.3390/antiox8040106. Review.

3.

Allyl isothiocyanate regulates lysine acetylation and methylation marks in an experimental model of malignant melanoma.

Mitsiogianni M, Mantso T, Trafalis DT, Vasantha Rupasinghe HP, Zoumpourlis V, Franco R, Botaitis S, Pappa A, Panayiotidis MI.

Eur J Nutr. 2019 Feb 14. doi: 10.1007/s00394-019-01925-6. [Epub ahead of print]

PMID:
30762097
4.

Bevacizumab, temsirolimus plus or without cetuximab: combinational treatment against patients with advanced HNSCC.

T Trafalis D, Alifieris C.

J BUON. 2018 Nov-Dec;23(6):1928-1929. No abstract available.

5.

Novel Docosahexaenoic Acid Ester of Phloridzin Inhibits Proliferation and Triggers Apoptosis in an In Vitro Model of Skin Cancer.

Mantso T, Trafalis DT, Botaitis S, Franco R, Pappa A, Rupasinghe HPV, Panayiotidis MI.

Antioxidants (Basel). 2018 Dec 11;7(12). pii: E188. doi: 10.3390/antiox7120188.

6.

Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.

Constantinidou A, Alifieris C, Trafalis DT.

Pharmacol Ther. 2019 Feb;194:84-106. doi: 10.1016/j.pharmthera.2018.09.008. Epub 2018 Sep 28. Review.

PMID:
30268773
7.

Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.

Tampaki EC, Tampakis A, Alifieris CE, Krikelis D, Pazaiti A, Kontos M, Trafalis DT.

Clin Drug Investig. 2018 Jul;38(7):639-648. doi: 10.1007/s40261-018-0655-z.

PMID:
29744672
8.

Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma.

Trafalis DT, Alifieris CE, Kalantzis A, Verigos KE, Vergadis C, Sauvage S.

J Immunother. 2018 Jul/Aug;41(6):300-305. doi: 10.1097/CJI.0000000000000221.

PMID:
29642086
9.

Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A propos of a case.

Karamanakos PN, Trafalis DT, Papachristou DJ, Panteli ES, Papavasilopoulou M, Karatzas A, Kardamakis D, Nasioulas G, Marselos M.

J BUON. 2017 Sep-Oct;22(5):1227-1232.

10.

Evidence of the role of the vagal nerves as a monitor in the gastrointestinal-renal axis of natriuresis in human: Effects of vagotomy.

Alifieris CE, Trafalis DT, Efstratopoulos AD, Alifieris EK.

Auton Neurosci. 2017 Jul;205:99-109. doi: 10.1016/j.autneu.2017.05.005. Epub 2017 May 10.

PMID:
28511917
11.

Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.

Trafalis DT, Polonifi A, Dalezis P, Nikoleousakos N, Katsamakas S, Sarli V.

Chem Biol Drug Des. 2017 Nov;90(5):854-866. doi: 10.1111/cbdd.13006. Epub 2017 May 26.

PMID:
28432813
12.

Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model.

Dalezis P, Trafalis DT, Geromichalos GD, Pissimissis N, Panagiotopoulou D, Galaktidou G, Papageorgiou E, Papageorgiou A, Lymperi M, Koutsilieris M.

Anticancer Drugs. 2017 Jun;28(5):489-502. doi: 10.1097/CAD.0000000000000484.

PMID:
28272098
13.

A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors.

Alifieris CE, Orfanakos K, Papanota A, Stathopoulos GP, Sitaras N, Trafalis DT.

J Cancer Res Clin Oncol. 2017 Apr;143(4):717-725. doi: 10.1007/s00432-016-2339-5. Epub 2017 Jan 11.

PMID:
28078434
14.
15.
16.

Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.

Trafalis DT, Alifieris C, Stathopoulos GP, Sitaras N.

Cancer Chemother Pharmacol. 2016 Apr;77(4):713-22. doi: 10.1007/s00280-016-2983-0. Epub 2016 Feb 18.

PMID:
26891956
17.

Glioblastoma multiforme: Pathogenesis and treatment.

Alifieris C, Trafalis DT.

Pharmacol Ther. 2015 Aug;152:63-82. doi: 10.1016/j.pharmthera.2015.05.005. Epub 2015 May 2. Review.

PMID:
25944528
18.

Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies.

Geromichalos GD, Lamari FN, Papandreou MA, Trafalis DT, Margarity M, Papageorgiou A, Sinakos Z.

J Agric Food Chem. 2012 Jun 20;60(24):6131-8. doi: 10.1021/jf300589c. Epub 2012 Jun 11.

PMID:
22655699
19.

Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.

Trafalis DT, Alifieris C, Krikelis D, Tzogkas N, Stathopoulos GP, Athanassiou AE, Sitaras NM.

Int J Clin Pharmacol Ther. 2012 Jul;50(7):490-9. doi: 10.5414/CP201688.

PMID:
22578202
20.

Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?

Trafalis DT, Alifieris C, Dalezis P, Geromichalos G, Sitaras NM.

Anticancer Drugs. 2012 Sep;23(8):874-82. doi: 10.1097/CAD.0b013e3283538c3d.

PMID:
22510794

Supplemental Content

Loading ...
Support Center